Amgen IncNASDAQ:AMGN
- LAST PRICE296.3915
- TODAY'S CHANGE (%)1.8615 (0.6320%)
- Bid / Lots295.9500/ 6
- Ask / Lots296.4200/ 1
- Open / Previous Close293.5500 / 294.5300
- Day Range
- 52 Week Range
- Volume99,954
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMGN |
|---|---|---|
| 09:32 ET | 38820 | 294.415 |
| 09:33 ET | 17508 | 295.15 |
| 09:35 ET | 3312 | 294.9614 |
| 09:37 ET | 4414 | 295.67 |
| 09:39 ET | 2918 | 296.3915 |
Nov 22, 2024
DJ The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's, from 9:30PM ET on Friday Nov 22, 2024 by Dow Jones
9:30PM ET on Friday Nov 22, 2024 by Dow Jones
Nov 21, 2024
DJ Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com, from 2:00AM ET on Thursday Nov 21, 2024 by Dow Jones
2:00AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 20, 2024
DJ Amgen Names Howard Chang as Chief Scientific Officer, from 4:23PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:23PM ET on Wednesday Nov 20, 2024 by Dow JonesAMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT, from 4:00PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:00PM ET on Wednesday Nov 20, 2024 by Dow JonesPress Release: AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT, from 4:00PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:00PM ET on Wednesday Nov 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amgen Inc | 158.3B | 37.9x | -0.22% |
Gilead Sciences Inc | 112.4B | 1,086.0x | +1.53% |
Bristol-Myers Squibb Co | 119.4B | -16.7x | +4.90% |
AstraZeneca PLC | 204.4B | 31.9x | +17.52% |
Sanofi SA | 123.8B | 26.0x | +4.55% |
Haleon PLC | 43.3B | 29.0x | --- |
Company Information
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Contact Information
- Headquarters
- One Amgen Center DriveTHOUSAND OAKS, CA, United States 91320
- Phone
- 805-447-1000
- Fax
- 805-447-1010
Executives
- Chairman of the Board, President, Chief Executive Officer
- Robert Bradway
- Chief Financial Officer, Executive Vice President
- Peter Griffith
- Executive Vice President, Chief Technology Officer
- David Reese
- Executive Vice President, Research and Development, and Chief Scientific Officer
- James Bradner
- Executive Vice President, General Counsel, Secretary
- Jonathan Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $158.3B |
|---|---|
Revenue (TTM) | $32.5B |
Shares Outstanding | 537.5M |
Dividend Yield | 3.04% |
Annual Dividend Rate | 9.0000 USD |
Ex-Dividend Date | 11-18-24 |
Pay Date | 12-09-24 |
Beta | 0.56 |
EPS | $7.82 |
Book Value | $11.64 |
P/E Ratio | 37.9x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | 16.1x |
Operating Margin | 19.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
